Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. is positioned favorably for growth due to the expansion of its product DefenCath into total parenteral nutrition (TPN), which increases the eligible patient base and enhances revenue potential beyond 2027. The company's forecast indicates a substantial improvement in DefenCath pricing by 3x-5x based on the TDAPA formula and anticipates sales reaching between $100 million and $140 million by 2027, driven by changes in dialysis reimbursement practices. Additionally, the recent acquisition of Momenta is expected to contribute approximately $140 million in pro forma revenue, while achieving operational synergies exceeding $35 million shortly after, reinforcing Cormedix's stability and growth trajectory.

Bears say

Cormedix, Inc. issued disappointing revenue guidance for 2026 and 2027, with projected top-line sales of $300MM-$320MM falling significantly short of market consensus expectations of $423MM. The anticipated sales for its primary product, DefenCath, are expected to decline to $150MM-$170MM, which indicates a substantial decrease from prior year estimates and raises concerns about the product's competitive viability against generics and its potential for market capture. Additionally, market research highlights high discontinuation rates due to toxicity and interactions associated with its treatment regimens, creating further headwinds for the company's financial prospects.

CorMedix (CRMD) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CorMedix (CRMD) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.